Senzime AB
6YC
Company Profile
Business description
Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.
Contact
Verkstadsgatan 8
Uppsala753 23
SWET: +46 18515640
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.70 | 7.70 | 0.09% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,388.44 | 40.53 | 0.15% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,272.11 | 529.54 | 0.84% |
| NZX 50 Index | 13,032.57 | 30.49 | -0.23% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,630.40 | 0.60 | -0.01% |
| SSE Composite Index | 4,242.57 | 28.08 | 0.67% |